Study TEVAR arm size Follow-up period Required re-intervention (%) Indication for re-intervention
Jia et al. 2013
208
28.5 months
9 (4.3%)
Persistent endoleak (3/9) 6 Rupture of descending aorta (6/9)
Xiang et al. 2021
191
5 years
6 (4.1%)
RTAD (2 of 6) Type I endoleak (2/6) Dissection extension (1/6) AAA expansion (1/6)
Mizoguchi et al. 2017 36 41±21 months 2 (5.2%) Type Ia endoleak (2/2)
Gao et al. 2019
751
70 months* (IQR 48.8)
4.46%
RTAD (7/41) Endoleak (10/41) Distal SINE (10/41) Residual dissection/recurrence of symptoms (8/41) Penetrating aortic ulcer (1/41) Aneurysm (3/41) False aneurysm (2/41)
aT: Acute management by TEVAR (1-14 days from presentation), sT: Subacute management by TEVAR (15-90 days from presentation) * Data Median reported, and 22.9% of the cohort lost follow-up in this study. aT: Acute management by TEVAR (1-14 days from presentation), sT: Subacute management by TEVAR (15-90 days from presentation) * Data Median reported, and 22.9% of the cohort lost follow-up in this study. aT: Acute management by TEVAR (1-14 days from presentation), sT: Subacute management by TEVAR (15-90 days from presentation) * Data Median reported, and 22.9% of the cohort lost follow-up in this study. aT: Acute management by TEVAR (1-14 days from presentation), sT: Subacute management by TEVAR (15-90 days from presentation) * Data Median reported, and 22.9% of the cohort lost follow-up in this study. aT: Acute management by TEVAR (1-14 days from presentation), sT: Subacute management by TEVAR (15-90 days from presentation) * Data Median reported, and 22.9% of the cohort lost follow-up in this study.